This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Alzheimer disease (AD) results, in part, from the excess accumulation of the amyloid-β (Aβ) peptide as neuritic plaques in the brain. The short Aβ peptide is derived from the large transmembrane Aβ precursor protein (APP). The rate-limiting step in the production of Aβ from APP is mediated by the β-site APP-cleaving enzyme 1 (BACE1).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Long, J. M., Ray, B., & Lahiri, D. K. (2014). MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. The Journal of biological chemistry. https://doi.org/10.1074/jbc.m113.518241

Vancouver

Long JM, Ray B, Lahiri DK. MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. The Journal of biological chemistry. 2014. doi:10.1074/jbc.m113.518241. PMID: 24352696.

BibTeX

@article{long2014-24352696,
  author  = {Long, J. M. and Ray, B. and Lahiri, D. K.},
  title   = {{MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects}},
  journal = {The Journal of biological chemistry},
  year    = {2014},
  doi     = {10.1074/jbc.m113.518241},
  pmid    = {24352696},
  url     = {https://doi.org/10.1074/jbc.m113.518241}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

The short Aβ peptide is derived from the large transmembrane Aβ precursor protein (APP).
The rate-limiting step in the production of Aβ from APP is mediated by the β-site APP-cleaving enzyme 1 (BACE1).
Dysregulation of BACE1 levels leading to excess Aβ deposition is implicated in sporadic AD.
Thus, elucidating the full complement of regulatory pathways that control BACE1 expression is key to identifying novel drug targets central to the Aβ-generating process.

Why it matters

The microRNA miR-339-5p was found to lower BACE1 protein levels in human brain cell cultures, and its levels were reduced in brain tissue from Alzheimer's disease subjects. This identifies a possible regulatory pathway and drug target, but no treatment based on it has been tested in patients.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 44/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Journal of biological chemistry)
Journal's citation record	4 / 4	Journal of Biological Chemistry: journal h-index 780 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2014 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 187 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	13.4 citations a year over 14 year(s) since 2014
Impact for its field and year	3 / 6	Cited 7.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	2 / 4	Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Debomoy K. Lahiri: h-index 85 (OpenAlex, whole career)
Institution's track record	1 / 3	Indiana University School of Medicine: institution h-index 784 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 24352696)
Free to read	0 / 2	Behind a paywall — scores zero
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Risk genes beyond APOE

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →